Total revenue increased لشكة .straznica By 62%, during the last quarter of last year, to reach regarding 12 billion dollars.
The Executive Vice President of the Vaccines and Immunology Department at AstraZeneca Iskra Reis confirmed, in an interview with Al-Arabiya channel, that the decline in revenues related to Covid vaccines will be compensated by EVU Shield for groups unable to receive the vaccine.
She said, “We delivered 2.5 billion doses around the world last year, and this certainly plays a very important role in the results of the company that we are proud of today, but it is important to remember that we delivered vaccines at cost prices without making any profits, as we committed ourselves from the beginning to the global fight once morest the epidemic. This means that the role played by the vaccine in 2021 is almost zero, and we announced in the third quarter of last year that we will move to a reasonable price that will allow us to continue distributing vaccines globally, and we are still committed to delivering vaccines at cost to low-income countries.This means that the vaccine will play a small role in Our expectations for this year’s results.
Reese expects that the returns related to the Covid-19 vaccine portfolio as a whole will decline in 2022 due to the decrease in the need for vaccines, and this will be compensated mainly by the launch of EVU Shield, a new tool that the company has to fight Covid 19, and represents an effective long-term treatment for the production of antibodies and preventing infection or treating people with Covid .
“I am happy to say that one of the first countries to receive this treatment is in the Arab world, which are Egypt and the UAE. This treatment is intended for people who do not develop antibodies once morest Covid even following receiving vaccinations and need special treatment and protection. As you know, we have built the distribution network in the midst of a global epidemic, I do not need to tell you that establishing centers for the production of these vaccines is a very expensive and complex process, but at the same time we are open and discussing with companies in different regions of the world, including yours, and we are exploring opportunities to expand the global supply network and raise production capacity in the region.
She noted that taking into account the strong evidence that AstraZeneca vaccines work on all new mutations, including Omicron, and recent data that “our VaxZevria vaccine also works well as a booster dose, we are directing and focusing our efforts today on the distribution process and obtaining regulatory approvals for delivery of the third booster dose.” In this context, we are not focused on developing a new vaccine and believe that our vaccine will continue to play an important role as a vaccine and a booster dose in protection once morest the epidemic.”
